About: IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens
Creator	Miyamura, Tatsuo Ooka, Yoshihiko Kanda, Tatsuo Wu, Shuang Yokosuka, Osamu Arai, Makoto Chiba, Tetsuhiro Haga, Yuki Imazeki, Fumio Jiang, Xia Mikami, Shigeru Nakamoto, Shingo Nakamura, Masato Sasaki, Reina Yasui, Shin
Source	Medline; PMC
abstract	Aim. Eradication of hepatitis C virus (HCV) is still challenging even if interferon- (IFN-) free regimens with direct-acting antiviral agents (DAAs) for HCV-infected individuals are available in clinical practice. IFNL4 is a newly described protein, associated with human antiviral defenses. We investigated whether IFNL4 ss469415590 variant has an effect on the prediction of treatment response in HCV-infected patients treated with IFN-including regimens. Patients and Methods. In all, 185 patients infected with HCV genotype 1 treated with peg-IFN plus ribavirin, with or without telaprevir, were genotyped for IFNL4 ss469415590. We retrospectively investigated whether the role of IFNL4 ss469415590 variant and other factors could predict sustained virological response (SVR) in Japanese patients infected with HCV genotype 1. Results. There were 65.7%, 31.5%, and 2.8% patients in the IFNL4 ss469415590 TT/TT, TT/-G, and -G/-G groups, respectively. SVR rates were 82.1% or 49.3% in patients treated with peg-IFN plus ribavirin with or without telaprevir, respectively. IFNL4 ss469415590 variant and HCV viral loads or IFNL4 ss469415590 variant and early virological response were better predictors of SVR in patients treated with peg-IFN plus ribavirin with or without telaprevir, respectively. Conclusion. In the era of DAAs, measurement of IFNL4 ss469415590 variant could help the prediction of SVR in Japanese HCV genotype 1 infected individuals treated with IFN-including regimens.
has issue date	2014-12-08(xsd:dateTime)
bibo:doi	10.1155/2014/723868
bibo:pmid	25548683
has license	cc-by
sha1sum (hex)	04664a7294d8225fdbce7a22932f46b8462fa89c
schema:url	https://doi.org/10.1155/2014/723868
resource representing a document's title	IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens
has PubMed Central identifier	PMC4274707
has PubMed identifier	25548683
schema:publication	Int J Hepatol
resource representing a document's body	covid:04664a7294d8225fdbce7a22932f46b8462fa89c#body_text
is schema:about of	named entity 'Conclusion' named entity 'HCV' named entity 'HCV GENOTYPE' named entity 'ASSOCIATED WITH' named entity 'defenses' named entity 'viral' named entity 'retrospectively' named entity 'IFN' named entity 'early' named entity 'DAAs' named entity 'treated' named entity 'ribavirin' named entity 'genotype' named entity 'response' named entity 'predict' named entity 'treated' named entity 'patients' named entity 'response' named entity 'Japanese' named entity 'individuals' named entity 'telaprevir' named entity 'Aim' named entity 'Infected' named entity 'IFN' named entity 'IFN' named entity 'telaprevir' named entity 'ribavirin' named entity 'IFNL4' named entity 'clinical practice' named entity 'telaprevir' named entity 'genotyped' named entity 'interferon' named entity 'SVR' named entity 'genotype' named entity 'IFNL4' named entity 'IFN' named entity 'SVR' named entity 'HCV' named entity 'HCV' named entity 'IFNL4' named entity 'virological' named entity 'IFNL4' named entity 'Genotype' named entity 'IFN' named entity 'protein' named entity 'genotype' named entity 'IFNL3' named entity 'AstraZeneca' named entity 'RNA' named entity 'IFN' named entity 'ribavirin' named entity 'Japan' named entity 'chronic hepatitis' named entity 'amino acid' named entity 'ribavirin' named entity 'Taiho Pharmaceutical' named entity 'SVR' named entity 'polymorphisms' named entity 'IFNL3' named entity 'Bayer' named entity 'univariate analysis' named entity 'HCV' named entity 'SSRI' named entity 'IL28B' named entity 'real-time PCR' named entity 'United States' named entity 'RNA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software